Research May Help Focus Treatment for Kids With Cystic Fibrosis

FRIDAY, Feb. 18, 2022 (HealthDay News) -- Hundreds of new proteins that may be linked to cystic fibrosis have been identified by researchers and could point the way to better treatments for people with the genetic disease.

There is no cure for cystic fibrosis, which affects more than 90,000 people worldwide. It's caused when children inherit two mutated CFTR genes, one from each parent, resulting in defective CFTR proteins that trigger a dangerous buildup of mucous in the lungs and other organs.

Many of the newly discovered proteins interact with CFTR, according to the international team of researchers.

"We identified more than 400 proteins associated with either healthy or mutant CFTR, and have shown that some of them could predict the variability seen in patient symptoms and treatment responses," said principal investigator Igor Stagljar, a professor at the University of Toronto's Donnelly Centre for Cellular and Biomolecular Research.

"With a more comprehensive view of the CFTR protein interaction network, we can identify novel drug targets that should enable more patient-specific therapies," Stagljar added in a university news release.

The study was published Feb. 14 in the journal Molecular Systems Biology.

About 2,000 mutations of the CFTR gene have been linked with cystic fibrosis, and the use of drug treatments based on a patient's individual genetic profile is common.

While some of those treatments are highly successful by restoring function of the CFTR protein, there can be wide variations in treatment response, even among patients with the same CFTR mutation.

While it's long been suspected that those differences in treatment response are due to secondary genetic modifiers and environmental factors, these new findings strongly suggest that proteins associated with CFTR play a role, according to Stagljar.

One especially promising candidate identified by the team is the Fibrinogen-like 2 protein, believed to play a role in hepatitis, liver disease and immune function. 

"We think Fibrinogen-like 2 protein is a valuable drug target for cystic fibrosis, and we're now working with our collaborators to validate other proteins that turned up in this study and in genome-wide association studies," Stagljar said.

2018 Michael Gaddes Memorial Scholarship Recipients

Brooklyn Allison and Madeline Bertrand are each recipients of the Michael Gaddes Memorial Scholarships Funded by the Gaddes Foundation. Each student will receive $2,000 per year for two years. Brooklyn lives in Tennessee and will be attending Pellisippi State Community College to study Business Management. Madeline is from Illinois and plans to study marine biology.

Brooklyn wrote a note to the foundation:

"I am beyond grateful for the scholarship. I have a lung disease, Cystic Fibrosis, my parents have to pay a ton on my medical bills. Because of your kindness and generosity, I will be able to afford going to college. I am going to go to Pellissippi State Community College and then hopefully transfer to the University of Tennessee for a degree in Business Management. The dream is to become an office manager and you are helping that come closer and closer to being a reality. Again, I really appreciate the scholarship."

Support the Gaddes Foundation on Amazon Smile

Amazon is one of the most widely used websites in the world. Amazon customers can now elect to donate 0.5% of their purchase to the charity of their choice. This is all made possible by shopping on smile.amazon.com